Post navigation Ramaswamy-backed Ambros Therapeutics launches with $125M to develop pain drugRatio Therapeutics has Successfully Dosed the First Cohort in its Phase 1/2 Study Evaluating a Novel FAP-Targeted Radiopharmaceutical in Patients with Late-Stage Aggressive Sarcomas